<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30108">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01898117</url>
  </required_header>
  <id_info>
    <org_study_id>M13TNB</org_study_id>
    <secondary_id>2013-001484-23</secondary_id>
    <secondary_id>NL44403.031.13</secondary_id>
    <nct_id>NCT01898117</nct_id>
  </id_info>
  <brief_title>Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line Treatment in Advanced Triple Negative Breast Cancer</brief_title>
  <acronym>Triple-B</acronym>
  <official_title>Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line Treatment in Advanced Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Borstkanker Onderzoek Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor
      survival. TNBC can be divided into at least two molecular entities; BRCA-like and
      non-BRCA-like. In this trial we would like to investigate whether a molecular subgroup
      exists within TNBCs that derives a benefit from bevacizumab added to first line
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In preclinical studies the addition of bevacizumab to chemotherapy improves drug access in
      the tumor. In humans, bevacizumab monotherapy normalizes the tumor vascularization. It is
      presently unknown what molecular subtype would derive a progression free survival (PFS)
      benefit of the addition of bevacizumab to first line chemotherapy. There are indications
      that patients with high VEFGA and/or VEFGR-2 plasma levels derive most benefit.

      There are indications that TNBC that are BRCA-like are more sensitive to bifunctional
      alkylating and platinum agents than non-BRCA-like TNBCs, and relatively resistant to
      taxanes. Consequently, because TNBCs in general derive substantial benefit from taxanes, we
      anticipate that non-BRCA-like TNBCs are exquisitely sensitive to taxanes. Bevacizumab and
      paclitaxel are synergistic in preclinical models. Therefore we anticipate that bevacizumab
      added to paclitaxel confers a substantial progression-free survival benefit in non-BRCA-like
      patients. We would like to test these hypotheses in a prospective clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determine PFS in the different VEGFR2 levels</measure>
    <time_frame>Assessed up to 120 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prospectively analyze whether VEGFR2 plasma levels at baseline predict for differential progression-free survival (PFS) benefit of bevacizumab added to first line palliative chemotherapy in triple-negative breast cancer (TNBC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validate the BRCA-like test</measure>
    <time_frame>assessed up to 120 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Validate the BRCA-like test in predicting differential PFS with first line alkylating and platinum agents when compared to paclitaxel in TNBC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of PFS by adding bevacicumab</measure>
    <time_frame>assessed up to 120 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Validate that bevacizumab added to first line palliative chemotherapy improves PFS in TNBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define predictive biomarkers for PFS gain</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Define predictive biomarkers for PFS gain of the addition of bevacizumab to first line chemotherapy; test VEGFA amplification vs no amplification and PFS stratified by chemotherapy regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine PFS</measure>
    <time_frame>From date of randomization until dat of first documented progression or date of death, which ever comes first, assessed up to 120 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>etermine PFS regarding the efficacy of the two different first line chemotherapeutic regimens, regardless of bevacizumab yes or no, in the whole study group, and in the BRCA-like and non-BRCA-like TNBCs subgroups separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>assessed up to 120 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of overall survival (OS) for all (sub)group comparisons as pre-specified for PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of all study regimens</measure>
    <time_frame>Assessed  at 1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events will be graded according to  NCI Common Toxicity Criteria version 4.03</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Carbo/cyclo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbo/cyclo + Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Bevacizumab 10 mg/kg d1, 15 Q 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel + bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 90 mg/m2 d1, 8, 15 Bevacizumab 10 mg/kg d1, 15 Q 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbo/cyclo</intervention_name>
    <arm_group_label>Carbo/cyclo</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbo/cyclo + bevacizumab</intervention_name>
    <arm_group_label>Carbo/cyclo + Bevacizumab</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Bevazicumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel</arm_group_label>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + Bevacizumab</intervention_name>
    <arm_group_label>Paclitaxel + bevacizumab</arm_group_label>
    <other_name>Paclitaxel</other_name>
    <other_name>evazicumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed triple negative breast cancer

          -  Histological confirmation of triple negative breast cancer of a metastatic lesion is
             recommended

          -  Histological or cytological confirmation of metastatic breast cancer is required in
             case of normal CA 15.3 levels

          -  No previous cytotoxic therapy for metastatic disease

          -  Disease-free interval of at least 12 months after completion of adjuvant taxane
             and/or platinum compound therapy

          -  Measurable disease according to RECIST

          -  Informative sVEGFR2 level test result in plasma baseline samples (taken before
             treatment started)

          -  Informative BRCA-like test result on primary tumor or metastasis (up to 5% of
             patients with an unknown test result will be randomized)

          -  WHO performance status of 0 or 1

          -  Adequate bone marrow function: neutrophils ≥ 1.5 x 10E9 cells/l, platelets ≥100 x
             10E9 cells/l, Hb ≥ 6.2 mmol/l.

          -  Normal liver function: bilirubin &lt; 1.5 x upper limit of the normal range (ULN);
             alkaline phosphatase &lt; 2.5 x ULN (&lt; 5 x ULN in case of liver metastases, and &lt; 7 x
             ULN in case of bone metastases); transaminases (ASAT/ALAT) &lt; 2.5 x ULN (and &lt; 5 x ULN
             in case of liver metastases).

          -  Normal renal function:

               -  calculated (Cockcroft-Gault) or measured creatinine clearance &gt; 50 mL/min

               -  Urine dipstick for proteinuria &lt; 2+. Patients with &gt; 2+ proteinuria on dipstick
                  urinalysis at baseline should undergo 24-hours urine collection and must
                  demonstrate ≤1 g of protein/24hr.

          -  INR &lt; 1.5 and APTT normal, unless patient is on stable anti-coagulant treatment for
             at least two weeks with a low molecular weight heparin or coumarin, then an INR
             within the target range (usually between 2 and 3) is allowed.

          -  Written informed consent

        Exclusion Criteria:

          -  Receptor conversion to hormone receptor positive (defined as &gt;= 1% positive ER or PgR
             tumor cells) or HER2 positive

          -  Another cancer except basal-cell carcinoma of the skin or in situ cervical cancer
             within the previous 5 years

          -  Other antitumor therapy within the previous 21 days

          -  Known CNS disease except for treated brain metastases.

          -  Uncontrolled serious medical or psychiatric illness

          -  Pre-existing peripheral neuropathy &gt; grade 1  (NCI-CTC AE (version 4.03)) at
             inclusion

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
             abscess within 6 months of randomization

          -  An infection requiring parenteral antibiotic

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to randomization or anticipation of need for major surgical procedure during
             the course of the study

          -  Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or
             recent peripheral arterial thrombosis within 6 months prior to randomization)

          -  Non healing wound or non healing fracture

          -  Arterial or venous thrombosis ≤ 12 months prior to registration

          -  Inadequate controlled hypertension (systolic &gt; 140 mm Hg and/or diastolic  &gt; 90 mm
             Hg)

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association Class II or greater congestive heart failure. LVEF by MUGA
             or ultrasound must be ≥ 50% and should be performed within 4 weeks prior to
             randomization if cardiac failure is suspected.

          -  History of myocardial infarction or unstable angina within 6 months prior to
             randomization

          -  History of stroke or transient ischemic attack within 6 months prior to randomization

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation)

          -  History of hemoptysis within 1 month prior to randomization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sabine C Linn, Prof. MD</last_name>
    <phone>+3120512</phone>
    <phone_ext>2870</phone_ext>
    <email>s.linn@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingrid A. Mandjes, MSc</last_name>
    <phone>+3120512</phone>
    <phone_ext>2667</phone_ext>
    <email>i.mandjes@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MCA</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S Vrijaldenhoven, MD</last_name>
    </contact>
    <investigator>
      <last_name>S Vrijaldenhoven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZGT</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I M Oving, MD</last_name>
      <email>i.oving@zgt.nl</email>
    </contact>
    <investigator>
      <last_name>I M Oving, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sabine C Linn, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZVU</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>I R Konings, MD</last_name>
      <email>m.konings@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>I R Konings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BovenIJ</name>
      <address>
        <city>Amsterdam</city>
        <zip>1034 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S E Dohmen, MD</last_name>
      <email>s.dohmen@bovenij.nl</email>
    </contact>
    <investigator>
      <last_name>S E Dohmen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lievensberg ziekenhuis</name>
      <address>
        <city>Bergen op Zoom</city>
        <zip>4624 VT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M M Troost, MD</last_name>
      <email>M.Troost@lievensberg.nl</email>
    </contact>
    <investigator>
      <last_name>M M Troost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <zip>1940 EB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R C Rietbroek, MD</last_name>
      <email>rrietbroek@rkz.nl</email>
    </contact>
    <investigator>
      <last_name>R C Rietbroek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IJsselland ziekenhuis</name>
      <address>
        <city>Capelle aan de IJssel</city>
        <zip>2906 ZC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D F Kehrer, MD</last_name>
    </contact>
    <investigator>
      <last_name>D F Kehrer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haga</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J E Portielje, MD</last_name>
      <email>j.portielje@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>J E Portielje, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A L Imholz, MD</last_name>
      <email>imholza@dz.nl</email>
    </contact>
    <investigator>
      <last_name>A L Imholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nijsmellinghe</name>
      <address>
        <city>Drachten</city>
        <zip>9202 NN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S Hovenga, MD</last_name>
      <email>s.hovenga@nijsmellinghe.nl</email>
    </contact>
    <investigator>
      <last_name>S Hovenga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A W Haringhuizen, MD</last_name>
      <email>haringhuizena@zgv.nl</email>
    </contact>
    <investigator>
      <last_name>A W Haringhuizen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M W Dercksen, MD</last_name>
    </contact>
    <investigator>
      <last_name>M W Dercksen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groene Hart</name>
      <address>
        <city>Gouda</city>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B C Tanis, MD</last_name>
      <email>bea.tanis@ghz.nl</email>
    </contact>
    <investigator>
      <last_name>B C Tanis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B de Valk, MD</last_name>
      <email>bdevalk@spaarneziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>B de Valk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MCL</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H de Graaf, MD</last_name>
      <email>graafhi@znb.nl</email>
    </contact>
    <investigator>
      <last_name>H de Graaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J R Kroep, MD</last_name>
      <email>j.r.kroep@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>J R Kroep, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MCH</name>
      <address>
        <city>Leidschendam</city>
        <zip>2262 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H M Oosterkamp, MD</last_name>
      <email>h.oosterkamp@mchaaglanden.nl</email>
    </contact>
    <investigator>
      <last_name>H M Oosterkamp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ikazia</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>F E de Jong, MD</last_name>
      <email>fe.de.jongh@ikazia.nl</email>
    </contact>
    <investigator>
      <last_name>F E de Jong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Fransicus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A P Hamberg, MD</last_name>
      <email>p.hamberg@sfg.nl</email>
    </contact>
    <investigator>
      <last_name>A P Hamberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vlietland ziekenhuis</name>
      <address>
        <city>Schiedam</city>
        <zip>3118 JH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Q C van Rossum-Schornagel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Q C van Rossum-Schornagel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J M van Riel, MD</last_name>
      <email>jmgriel@elisabeth.nl</email>
    </contact>
    <investigator>
      <last_name>J M van Riel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tweesteden ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H Th Roerdink, MD</last_name>
      <email>hroerdink@tsz.nl</email>
    </contact>
    <investigator>
      <last_name>H Th Roerdink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A H. Honkoop, MD</last_name>
      <email>a.h.honkoop@isala.nl</email>
    </contact>
    <investigator>
      <last_name>A H Honkoop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>June 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple negative</keyword>
  <keyword>Metastatic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
